The increased efficacy of targeted alpha and beta therapies using radiopharmaceuticals such as Lu-177 and Ac-225 has significantly transformed the treatment landscape for neuroendocrine tumors and prostate cancers. These isotopes have demonstrated high precision in targeting cancerous cells, delivering potent radiation directly to the tumor sites while minimizing damage to surrounding healthy tissues. Lu-177, particularly in combination with Peptide Receptor Radionuclide Therapy (PRRT), has shown remarkable success in treating neuroendocrine tumors, while Ac-225's powerful alpha-emission properties make it highly effective in targeting and destroying prostate cancer cells, especially those resistant to conventional therapies. This proven efficacy has driven rapid clinical adoption and acceptance within oncology practices. As these therapies continue to show positive outcomes, they contribute directly to the expansion of the market, fueling growth in both diagnostic and therapeutic applications.
Access Full Reports @ https://www.databridgemarketresearch.com/reports/global-alpha-and-beta-emitters-based-radiopharmaceuticals-market
Data Bridge Market Research analyzes that the Global Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach USD 1,769.20 million by 2032 from USD 801.45 million in 2024, growing at a substantial CAGR of 10.4% in the forecast period of 2025 to 2032.
Key Findings of the Study
Growing Adoption of Theranostics in Personalized Medicine
The rising adoption of theranostic approaches is revolutionizing the radiopharmaceuticals market, with isotopes such as Terbium-161 (Tb-161) and Lutetium-177 (Lu-177) playing pivotal roles. These radionuclides are utilized in both diagnostic imaging and targeted radiotherapy, enabling seamless integration of disease detection and treatment within a single clinical workflow. This dual functionality enhances precision in patient selection, treatment planning, and monitoring, significantly advancing the promise of personalized medicine. By streamlining care and improving patient outcomes through targeted interventions, theranostics drives increased clinical acceptance and investment, acting as a key growth driver for the radiopharmaceuticals market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2025 to 2032
|
|
Base Year
|
2024
|
|
Historic Year
|
2023 (Customizable 2013-20217)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Netherlands, Poland, Norway, Austria, Ireland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Peru, Chile, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Novartis AG (Switzerland), Eckert & Ziegler Germany), ITM Isotope Technologies Munich SE (Germany), SHINE Technologies, LLC (U.S.), Actinium Pharmaceuticals, Inc. (U.S.), Alpha Tau Medical Ltd. (Israel), ARICEUM THERAPEUTICS (Germany), Bayer AG (Germany), Curium (U.S.), IONETIX Corporation (U.S.), Isotopia (Israel), Lantheus (U.S.), Lilly (U.S.), Niowave (U.S.), NMR (U.S.), Oncoinvent (Norway), Orano Group (Paris), Radiopharm Theranostics Limited (Australia), Telix Pharmaceuticals Limited (Australia), and Terthera (Netherlands) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Global alpha and beta emitters based radiopharmaceuticals market is segmented into five notable segments which are based on the isotope, sources, therapeutic application, vector type, and end user.
- On the basis of isotope, global alpha and beta emitters based radiopharmaceuticals market is segmented into beta emitters and alpha emitters
In 2025, the beta emitters segment is expected to dominate the global alpha and beta emitters based radiopharmaceuticals market
In 2025, the beta emitters segment is expected to dominate the market with a market share of 84.78% due to their established clinical use, broader availability, and proven efficacy in treating cancers such as prostate and neuroendocrine tumors. Widely adopted therapies such as lutetium-177–based radioligands continue to drive demand across oncology practices.
- On the basis of sources, global alpha and beta emitters based radiopharmaceuticals market is segmented into reactor-produced isotopes, generator-produced isotopes, and others
In 2025, the reactor-produced isotopes segment is expected to dominate the global alpha and beta emitters based radiopharmaceuticals market
In 2025, the reactor-produced isotopes segment is expected to dominate the market with a market share of 61.91% due to their high production capacity, cost-effectiveness, and established infrastructure. These isotopes, such as lutetium-177, are widely used in approved therapies, making them a reliable source for large-scale clinical applications.
- On the basis of therapeutic application, global alpha and beta emitters based radiopharmaceuticals market is segmented into oncology and others. In 2025, the oncology segment is expected to dominate the market with a market share of 77.11%
- On the basis of vector type, global alpha and beta emitters based radiopharmaceuticals market is segmented into small molecule ligands, peptides, monoclonal antibodies, and others. In 2025, the small molecule ligands segment is expected to dominate the market with a market share of 51.84%
- On the basis of end user, global alpha and beta emitters based radiopharmaceuticals market is segmented into hospitals, radiopharmacies, and research institutes. In 2025, the hospitals segment is expected to dominate the market with a market share of 56.82%
Major Players
Data Bridge Market Research analyzes Novartis AG (Switzerland), Eckert & Ziegler Germany), ITM Isotope Technologies Munich SE (Germany), and SHINE Technologies, LLC (U.S.) as the major market players of the global alpha and beta emitters based radiopharmaceuticals market.
Market Developments
- In March 2025, the FDA approved Novartis’ Pluvicto (Lu-177 vipivotide tetraxetan) for earlier use in PSMA-positive metastatic castration-resistant prostate cancer, allowing administration after one ARPI and before chemotherapy. Based on Phase III PSMAfore trial results, Pluvicto reduced progression or death risk by 59%, doubling median radiographic progression-free survival while maintaining a favorable safety profile and expanding patient access significantly
- In May 2024, Novartis AG announced its agreement to acquire Mariana Oncology for USD 1 billion upfront and up to USD 750 million in milestone payments. The acquisition strengthens Novartis’ radioligand therapy (RLT) pipeline with preclinical assets targeting solid tumors, including actinium-based candidate MC-339 for small cell lung cancer, and enhances its RLT research, supply, and innovation capabilities
- In March 2025, Eckert & Ziegler and AtomVie Global Radiopharma signed a global supply agreement for non-carrier added Lutetium-177 (Theralugand). The partnership ensures a stable, high-quality Lu-177 supply for AtomVie’s CDMO radiopharmaceutical operations, supporting early-to-late-stage development worldwide and enhancing both companies' capabilities in radiopharmaceutical innovation, regulatory compliance, and patient-centered nuclear medicine solutions
- In May 2025, ITM Isotope Technologies Munich SE and Radiopharm Theranostics announced a supply agreement for non-carrier-added Lutetium-177 (n.c.a. 177Lu). The partnership supports Radiopharm’s clinical development of Lu-177-based therapies, including RAD 204, RAD 202, and RV01, ensuring high-quality isotope access for targeted radiopharmaceutical treatment of solid tumors in ongoing and future clinical trials
- In March 2025 , Eckert & Ziegler and Actinium Pharmaceuticals signed a supply agreement for high-purity Actinium-225 (Ac-225). The partnership ensures a reliable Ac-225 source to support the development of Actimab-A and other radiotherapeutic candidates targeting AML and solid tumors, strengthening Actinium’s clinical pipeline and addressing global isotope supply challenges in precision radiopharmaceutical therapy
Regional Analysis
Geographically, the countries covered in the global alpha and beta emitters based radiopharmaceuticals market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Netherlands, Poland, Norway, Austria, Ireland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Peru, Chile, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to be the dominant and the fastest-growing region in the global alpha and beta emitters based radiopharmaceuticals market
North America is expected to dominate and the fastest-growing region the global alpha and beta emitters based radiopharmaceuticals market due to its advanced healthcare infrastructure, strong presence of key pharmaceutical companies, and high adoption of innovative targeted radionuclide therapies. In addition, increasing cancer prevalence and substantial investment in research and development further drive market growth in the region.
For more detailed information about the global alpha and beta emitters based radiopharmaceuticals market report, click here – https://www.databridgemarketresearch.com/reports/global-alpha-and-beta-emitters-based-radiopharmaceuticals-market
